Skip to content
StockMarketAgent
Direct answer
MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $737, high $1308, with mid-point at $1016.
Stock analysis

MCK MCK fair value $737–$1,308

MCK
By StockMarketAgent.AI team· supervised by
Analysiert: 2026-05-13Nächste Aktualisierung: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Kurs
$725.17
▲ +290.95 (+40.12%)
Fair Value
$1016
$737–$1308
Rating
Starker Kauf
confidence 79/100
Aufwärtspotenzial
+40.1%
upside to fair value
Sicherheitsmarge
$863.70
MoS level · 15%
Marktkapitalisierung
$87.2B
P/E fwd 14.4
Englische QuelleDE
Englische Quelle wird angezeigt, während wir übersetzen
Dieser Bericht wurde noch nicht übersetzt. Aktualisieren Sie in ein paar Minuten, sobald die Übersetzungswarteschlange aufgeholt hat.

§1 Zusammenfassung

  • Composite fair value $1,016 with high case $1,308.
  • Implied upside of 40.1% to fair value.
  • Moat 9/10 · confidence 79/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$1,016
Margin of safety
+28.6%
Confidence
79/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$725.17Price
Low $737.34
Mid $1,016.12
High $1,307.92

MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Immense scale forming an entrenched
    Immense scale forming an entrenched oligopoly in US pharmaceutical distribution.
  • High barriers to entry due
    High barriers to entry due to extreme capital and regulatory requirements.
  • Cycle upside
    Aging demographics and expanded specialty drug approvals drive sustained volume growth.

§2 Bärenszenario

A stress scenario combining severe legislative pressure on drug prices with a sustained high-interest-rate environment would squeeze margins. If operating margins dip below 1.0% and the WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. normalizes to a higher tier, intrinsic valueIntrinsic valueThe discounted present value of all cash a business will produce over its remaining life. The theoretical anchor for fair value, computed in practice as a range across explicit assumptions. regressions toward the $737 downside boundary.

Wie diese These scheitern kann

Major Retail Network Loss

· Low

The loss of a massive retail pharmacy network customer significantly impairs revenue volume and devastates operating leverage.

FV impact
-25%

Regulatory Margin Collapse

· Medium

Aggressive legislative action on drug pricing and PBM models compresses already razor-thin operating margins below 1.0%.

FV impact
-30%

Resurgent Litigation

· Low

Unexpected expansion of opioid-related liabilities or new mass torts drain free cash flow, threatening the share buyback program.

FV impact
-15%
Frühwarnsignale zur Überwachung
KennzahlAktuellAuslöseschwelle
Operating margins slipping below 1.2% for consecutive quarters.MonitorDeterioration versus the report thesis
Cancellation or significant reduction of the annual share repurchase program.MonitorDeterioration versus the report thesis
Loss of major customer contracts in the retail pharmacy segment.MonitorDeterioration versus the report thesis
Slowing revenue growth in the higher-margin specialty oncology segment.MonitorDeterioration versus the report thesis
Deteriorating free cash flow conversion ratios.MonitorDeterioration versus the report thesis

§3 Finanzielle Historie

Gewinn- und Verlustrechnung — letzte sechs Perioden
PositionT−0T−1T−2T−3CAGR
Periode2022-03-312023-03-312024-03-312025-03-31Trend
Umsatz$263.97B$276.71B$308.95B$359.05B+10.8%
Bruttogewinn$13.13B$12.36B$12.83B$13.32B+0.5%
Betriebsergebnis$2.59B$4.58B$4.17B$4.82B+22.9%
Nettogewinn$1.11B$3.56B$3.00B$3.30B+43.5%
EPS (verwässert)$7.23$25.03$22.39$25.72+52.7%
EBITDA$2.87B$5.49B$4.68B$5.26B+22.4%
F&E
VVG$10.54B$7.78B$8.66B$8.51B-6.9%

Qualitäts-Scores

OCF / Nettogewinn
1.85×
>1 weist auf hohe Ergebnisqualität hin
Bilanzqualitätsschwelle
Fail
Sektoradjustierte Schwelle
ROIC
68.7%
Rendite auf eingesetztes Kapital
Abschnitt 3

Numbers analysis

Cashflow

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Kapitalallokation

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Einzelabonnenten — ab §411 weitere Abschnitte

Vollständige Analyse lesen — 11 weitere Abschnitte.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Vollständiger Bericht für jeden abgedeckten Ticker
24 Monate Rating-Archiv
Watchlist-Briefings + Rating-Änderungs-Warnungen
PDF + DOCX Export in jeder Sprache
Kostenlose Testversion starten
Jederzeit kündbar.
FAQ

MCK — frequently asked questions

  1. Based on our latest analysis, MCK looks meaningfully undervalued. The current price is $725 versus a composite fair-value midpoint of $1016 (range $737–$1308), which implies roughly 40.1% upside to the midpoint.
Related coverage

Names readers of MCK also follow

Same archetype: mature-compounder